Gylden Pharma
We work on addressing some of the world’s most impactful health threats with a growing pipeline of candidates. Gylden’s T cell-priming vaccine and immunotherapy candidates combine core proprietary technologies. First indications pursued protect against infectious diseases: (1) including core candidates for Betacoronavirus, Dengue Fever, and Universal Influenza (including Pandemic Influenza); as well as (2) intra-cellular bacterial infectious diseases.
Private Company
Funding information not available
About
We work on addressing some of the world’s most impactful health threats with a growing pipeline of candidates. Gylden’s T cell-priming vaccine and immunotherapy candidates combine core proprietary technologies. First indications pursued protect against infectious diseases: (1) including core candidates for Betacoronavirus, Dengue Fever, and Universal Influenza (including Pandemic Influenza); as well as (2) intra-cellular bacterial infectious diseases.